What does this video actually claim?
Hope's TikTok is surprisingly vague for a platform known for bold health claims. She attributes her transformation to "the work" and mentions "the scale didn't change me," while hashtagging #amble and directing followers to her bio for a company link.
The video falls into the GLP-1 category, suggesting she's using semaglutide, tirzepatide, or a similar medication. But she doesn't explicitly name any drug or make specific medical claims. Instead, she focuses on mindset and effort while subtly promoting what appears to be a telehealth service.
This approach is actually smarter than most influencer health content. By keeping claims general, she avoids making false medical statements that could get her in trouble.
Does focusing on "the work" make sense with GLP-1s?
Hope's emphasis on effort over the scale matches well with how these medications actually function. GLP-1 receptor agonists like semaglutide don't magically melt fat while you sleep.
The STEP 1 trial (Wilding et al., NEJM, 2021) showed 14.9% weight loss with 2.4mg semaglutide, but participants also received lifestyle counseling every four weeks. The medication group that lost the most weight combined the drug with consistent dietary changes.
Tirzepatide performed even better in the SURMOUNT-1 study (Jastreboff et al., NEJM, 2022), with 22.5% weight loss at the highest dose. But again, this wasn't just medication. Participants got intensive lifestyle support throughout the 72-week trial.
So yes, "the work" matters enormously. These drugs reduce appetite and slow gastric emptying, but you still need to make better food choices when you're less hungry.
What's misleading about this approach?
While Hope avoids false claims, her vague messaging could mislead followers about what they're actually signing up for. The #amble hashtag likely refers to a specific telehealth platform, but she doesn't clearly disclose this business relationship.
More problematic is the implication that mindset alone drove her results. GLP-1 medications are powerful tools that fundamentally change hunger signals. The SELECT trial (Lincoff et al., NEJM, 2023) showed semaglutide reduced major cardiovascular events by 20% in people without diabetes.
These aren't lifestyle supplements. They're serious medications with real side effects like nausea, vomiting, and potential pancreatitis. Presenting them as secondary to "mindset" minimizes the medical nature of the intervention.
Hope also skips any mention of side effects, which affect most users initially. In STEP 1, 74.2% of participants experienced gastrointestinal adverse events.
What should you actually know about GLP-1s?
If you're considering these medications, understand they're prescription drugs requiring medical supervision. Starting doses are deliberately low (0.25mg for semaglutide) to minimize side effects, with gradual increases over months.
The weight loss is real and substantial for most people. Across major trials, average weight loss ranges from 12-22% depending on the specific medication and dose. But about 10-15% of people don't respond well to any GLP-1 drug.
Cost remains a major barrier. Without insurance coverage, expect $800-1,200 monthly for brand-name versions. Some telehealth platforms offer compounded versions for less, though FDA oversight varies.
Hope gets credit for not overpromising quick fixes or dramatic health claims. Her focus on sustained effort reflects how these medications work best when combined with genuine lifestyle changes, not as magic bullets.